A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.
Drug repurposing study finds lonafarnib effective against RSV
- Post author:
- Post published:February 11, 2024
- Post category:uncategorized